{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.2","upperLimit":"3.1","value":"2.6"},{"groupId":"OG001","lowerLimit":"1.2","upperLimit":"3.0","value":"1.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"},{"groupId":"OG001","value":"107"}],"units":"Participants"}],"description":"Time to response (TTR), calculated for those participants with an objective response, is defined as the time from the randomization date to the date of first objective response.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Cetuximab 400 mg/m\\^2 as an initial dose, followed by 250 mg/m\\^2 intravenously (IV) every 7 days.","id":"OG000","title":"Cetuximab"},{"description":"Panitumumab 6 mg/kg IV every 14 days.","id":"OG001","title":"Panitumumab"}],"paramType":"MEDIAN","populationDescription":"Participants with an objective response","reportingStatus":"POSTED","timeFrame":"From randomization until the data cut-off date of 5 February 2013. Maximum time on study was 155 weeks.","title":"Time to Response","type":"SECONDARY","unitOfMeasure":"months"}